Our results also suggest that peri-event PCSK9 concentrations may be associated with increased risk of subsequent loss of ventricular function in some patient populations, and that PCSK9 inhibition with antibodies or gene-silencing interventions may constitute an interesting target for the preservation of LVEF in patients with MI. Here, PCSK9 is linked to myocardial infarction.